SCHEMBL2127254

SCHEMBL2127254

CCCCCCCCCCCCCCCC(=O)O[C@@]12[C@H](O)[C@@H](C)[C@@]3(O)[C@@H](C=C(CO)C[C@]4(O)C(=O)C(C)=C[C@@H]34)[C@H]1C2(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 6/20 0.79
PRKCG P05129 6/20 0.78
PRKCB P05771 5/20 0.78
PRKCH P24723 5/20 0.78
PRKCE Q02156 5/20 0.78
PRKCQ Q04759 5/20 0.78
PRKCD Q05655 5/20 0.78
PRKD3 O94806 4/20 0.78
PRKCI P41743 4/20 0.78
PRKCZ Q05513 4/20 0.78
PRKD1 Q15139 4/20 0.78
USP2 O75604 2/20 0.78
TP53 P04637 2/20 0.78
KDM4E B2RXH2 1/20 0.78
ALDH1A1 P00352 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
CYP3A4 P08684 1/20 0.78
CYP2C9 P11712 1/20 0.78
TSHR P16473 1/20 0.78
NFKB1 P19838 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16922839 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL312634 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL18627982 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL8192421 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL22171801 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL21578359 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL18210530 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL892726 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL16904300 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL18210529 0.99 PRKCA (0.81) PRKCAPRKCGPRKCBPRKCHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10948480-B2 Immunity to folate receptors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-03-16 US disclosed
US-9915646-B2 Immunity to folate receptors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2018-03-13 US disclosed
US-20160131638-A1 IMMUNITY TO FOLATE RECEPTORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-05-12 US disclosed
US-9243033-B2 Immunity to folate receptors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2016-01-26 US disclosed
US-20140212443-A1 IMMUNITY TO FOLATE RECEPTORS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2014-07-31 US disclosed
US-8486412-B2 Immunity to folate receptors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2013-07-16 US disclosed
EP-1356277-B1 METHOD FOR ALTERING CELL FATE KYOWA HAKKO KIRIN CO LTD (JP) 2012-04-25 EP disclosed
US-20100272741-A1 IMMUNITY TO FOLATE RECEPTORS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2010-10-28 US disclosed
US-7736895-B2 Methods for altering cell fate KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-15 US disclosed
US-7491534-B2 Methods for altering cell fate to generate T-cells specific for an antigen of interest KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2009-02-17 US disclosed
EP-0181455-B2 Use of preparations containing interferon-gamma (IFN-gamma) for systematically treating various human diseases at a low dosage BOEHRINGER INGELHEIM INT (DE) 2000-05-31 EP disclosed
EP-0373335-B1 Serine protease inhibitor proteins, medicaments containing them, DNA sequences coding for these proteins and methods for producing these proteins, medicaments and DNA sequences GRUENENTHAL GMBH (DE) 1997-12-10 EP disclosed
EP-0767840-A2 METHOD FOR INTRODUCING FOREIGN MATTER INTO HIGHER EUKARYOTIC CELLS BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 1997-04-16 EP disclosed
WO-1995033062-A2 METHOD FOR INTRODUCING FOREIGN MATTER INTO HIGHER EUKARYOTIC CELLS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 1995-12-07 WO disclosed
EP-0373335-A2 Serine protease inhibitor proteins, medicaments containing them, DNA sequences coding for these proteins and methods for producing these proteins, medicaments and DNA sequences Grünenthal GmbH (DE) 1990-06-20 EP disclosed
EP-0180737-B1 USE OF INTERFERON GAMMA (IFN-GAMMA) FOR THE PRODUCTION OF PREPARATIONS FOR TREATING RHEUMATIC DISEASES BIOFERON BIOCHEM SUBSTANZ (DE) 1989-08-23 EP disclosed
EP-0205629-A1 Use of preparations containing gamma interferon (IFN-gamma) for treating rheumatic diseases BIOFERON Biochemische Substanzen GmbH & Co i.K. (DE) 1986-12-30 EP disclosed
EP-0181455-A2 Use of preparations containing interferon-gamma (IFN-gamma) for systematically treating various human diseases at a low dosage Dr. Rentschler Biotechnologie GmbH (DE) 1986-05-21 EP disclosed
EP-0180737-A2 Use of interferon gamma (IFN-gamma) for the production of preparations for treating rheumatic diseases Dr. Rentschler Biotechnologie GmbH (DE) 1986-05-14 EP disclosed
EP-0177910-A2 Use of preparations containing gamma-interferon (IFN-gamma) for systematically treating various human diseases at a low dosage BIOFERON Biochemische Substanzen GmbH & Co i.K. (DE) 1986-04-16 EP disclosed